Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)

This study is ongoing, but not recruiting participants.
National Data Bank for Rheumatic Diseases (NDB)
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: March 12, 2010
Last updated: November 19, 2015
Last verified: November 2015
The purpose of this study is to compare the incidence rates of targeted infections, malignancies and mortality among patients with rheumatoid arthritis who are treated with abatacept and those who are treated with other anti-rheumatic medications.

Rheumatoid Arthritis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Observational Cohort to Assess Safety and Outcomes in Patients Treated With Abatacept and Other Anti-Rheumatic Therapies

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Key safety outcomes (targeted infections, malignancies, mortality) [ Time Frame: Every 6 months throughout the study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Patient-reported infusion reactions [ Time Frame: Every 6 months throughout the study ] [ Designated as safety issue: Yes ]
  • Multiple sclerosis, lupus, and psoriasis [ Time Frame: Every 6 months throughout the study ] [ Designated as safety issue: Yes ]
  • Adverse events in pregnant women who receive abatacept [ Time Frame: Every 6 months throughout the study ] [ Designated as safety issue: Yes ]
  • Adverse events in subjects on abatacept who receive concomitant biologics [ Time Frame: Every 6 months throughout the study ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 20000
Study Start Date: March 2005
Estimated Study Completion Date: March 2017
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Patients with rheumatoid arthritis initiating abatacept
Pts with RA initiating other biologic disease-modifying drugs
Pts w/ RA non-biologic disease-modifying anti-rheumatic drugs


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients being treated for rheumatoid arthritis in the US

Inclusion Criteria:

  • Signed informed consent
  • Diagnosis of rheumatoid arthritis
  • > 18 years at index treatment initiation or switch
  • Starting treatment with abatacept or new disease-modifying anti-rheumatic drug (including switching or adding) or biologic disease modifying drug.
  • Read/write English

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01088360

Sponsors and Collaborators
Bristol-Myers Squibb
National Data Bank for Rheumatic Diseases (NDB)
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided

Responsible Party: Bristol-Myers Squibb Identifier: NCT01088360     History of Changes
Other Study ID Numbers: IM101-045B 
Study First Received: March 12, 2010
Last Updated: November 19, 2015
Health Authority: United States: Institutional Review Board
European Union: European Medicines Agency

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on February 11, 2016